AbCellera Biologics (ABCL) Profit After Tax: 2020-2023
Historic Profit After Tax for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$47.1 million.
- AbCellera Biologics' Profit After Tax fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
- Latest data reveals that AbCellera Biologics reported Profit After Tax of -$47.1 million as of Q4 2023, which was down 64.80% from -$28.6 million recorded in Q3 2023.
- AbCellera Biologics' 5-year Profit After Tax high stood at $168.6 million for Q1 2022, and its period low was -$47.1 million during Q4 2023.
- In the last 3 years, AbCellera Biologics' Profit After Tax had a median value of -$14.1 million in 2021 and averaged $13.8 million.
- Within the past 5 years, the most significant YoY rise in AbCellera Biologics' Profit After Tax was 5,700.62% (2021), while the steepest drop was 693.91% (2021).
- Over the past 4 years, AbCellera Biologics' Profit After Tax (Quarterly) stood at $117.0 million in 2020, then tumbled by 48.76% to $59.9 million in 2021, then crashed by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.1 million in 2023.
- Its last three reported values are -$47.1 million in Q4 2023, -$28.6 million for Q3 2023, and -$30.5 million during Q2 2023.